Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

22.2%

2 terminated/withdrawn out of 9 trials

Success Rate

75.0%

-11.6% vs industry average

Late-Stage Pipeline

33%

3 trials in Phase 3/4

Results Transparency

67%

4 of 6 completed trials have results

Key Signals

4 with results

Enrollment reporting

Analytics

Phase 3

3(37.5%)

Phase 2

2(25.0%)

Phase 1

2(25.0%)

Phase 1/2

1(12.5%)

8Total

Phase 3(3)

Phase 2(2)

Phase 1(2)

Phase 1/2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT05911399Unknown

Expanded Access Program for Tiratricol in Patients With Monocarboxylate Transporter 8 Deficiency

Role: collaborator

NCT05579327Phase 3Completed

Withdrawal of Tiratricol Treatment in Males With Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency)

Role: collaborator

NCT04034355Phase 3Terminated

Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy in Adjuvant Colorectal Cancer

Role: lead

NCT03654729Phase 3Terminated

Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M)

Role: lead

NCT03177395Phase 1Completed

PP100-01 (Calmangafodipir) for Overdose of Paracetamol

Role: lead

NCT01619423Phase 1/2Completed

A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer

Role: lead

NCT03430999Phase 1Completed

SUNCIST: A Study of Calmangafodipir in Healthy Japanese and Caucasian Subjects

Role: lead

NCT00966563Phase 2Completed

Mangafodipir as an Adjunct to Percutaneous Coronary Intervention

Role: lead

NCT00671996Phase 2Completed

Mangafodipir as an Adjunct to FOLFOX6 Chemotherapy in Colon Cancer Stage Dukes' C

Role: lead

All 9 trials loaded